Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IONIS-FB-LRX for geographic atrophy secondary to age-related macular degeneration
NL-OMON51185Phase 2Withdrawn
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jun 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sefaxersen in age-related macular degeneration (AMD) (4 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Absolute change in geographic atrophy area at Week 49. Planned start Jun 2021; status: withdrawn.
02
Drugs
sefaxersen
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NL-OMON51185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51185.